about
Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts.Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.Bone Marrow CD11c+ Cell-Derived Amphiregulin Promotes Pulmonary FibrosisLung bone marrow-derived hematopoietic progenitor cells enhance pulmonary fibrosis.A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung.MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model.Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis.Chronic Intestinal Pseudo-obstruction and Orthostatic Hypotension Associated with Small Cell Lung Cancer that Improved with Tumor Reduction after ChemoradiotherapySuplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals.AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma.The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.Clinically remitted childhood asthma is associated with airflow obstruction in middle-aged adults.Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis.Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility studyAnti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II StudyPlasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosisSerial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: A retrospective cohort studyPhotochemical generation of the 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) radical from caged nitroxides by near-infrared two-photon irradiation and its cytocidal effect on lung cancer cellsHigh preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgeryInhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblastsSuplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stressNicergoline improves dysphagia by upregulating substance P in the elderlyAminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesotheliomaAlbumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancerChemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung CancerPerformance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer PatientsIntratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in MiceSerum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosisNon-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with PolyangiitisRole of B7H3/IL-33 Signaling in Pulmonary Fibrosis-induced Profibrogenic Alterations in Bone MarrowComparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumoniaPulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization: Two case reportsCerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case reportC-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity PneumonitisPre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
P50
Q35918076-EE2CCA31-4EDD-46D1-B2E7-550AA48D059AQ36949126-5A25A12D-4028-4E20-AA73-8F0D88B73984Q37018469-6986E739-C501-4381-9E60-AE57C3081D7BQ37304394-AC1080CB-0026-426D-B498-D427C1573673Q38235637-E3B4CF9B-867A-412D-8977-274B83F6F9F5Q38857165-6736420F-D4E0-4290-94D2-3203B23F96DAQ42408410-8F73F98C-0902-49EC-9C41-1C95943EE874Q42607607-1056171F-5E80-4F5F-9BE4-E9BF60C4B2B6Q42620019-826E25B7-05EF-4814-B5E0-67AC4D3313EFQ46419204-52F72D2F-783E-415E-9505-4E9B4868824CQ47106968-CE69D53D-C921-467E-AA1C-2357D44008C5Q47216049-1048FDD4-23AA-4903-BD06-F5A14BF6DE42Q47747162-FA6B0463-D9DB-437C-9BAF-5ED8845CFE04Q51486307-1D216805-535D-4D9E-8DD9-462AB757C2D9Q52587605-06507859-FCDF-4D92-A4DE-3253A55B135FQ54564697-27754DD5-FBD8-49DC-9AE6-7DD2D1BA0447Q57788528-40D01984-A976-4923-98C8-4B5D0271277CQ58589945-409C608C-92B9-4BCB-BD6E-714561E1F261Q58765953-5EF59D24-D6E3-4418-AE07-8D7E7A0B5772Q58804675-AD1E75CC-D249-4639-992D-1810F2A37D27Q60961619-19BCF2B0-BE66-4163-A5C1-A1D5C88654E9Q64057855-69D449B0-B370-4752-9DAF-02788ED6F4E9Q64257051-2CDD841A-DD85-4D70-962A-32BEC1E62C92Q64279271-EFF2EE09-C428-494D-95B8-61F59FE735CCQ64387385-F0A8A69B-CCA8-47DB-91EC-7DA51C370E69Q84415085-1D4C813E-C553-4083-8F66-5B7AB8F95400Q88007639-C41FE929-E7FF-41B7-A506-6AF3CCBC85B6Q90156102-2B9DE9CB-6F57-41C0-B2FC-FB0C31B9DD87Q90388245-0439ECB5-EBC2-4BFC-878F-3052FD680BCEQ90647357-4A29F8BA-BAC4-4C13-9D70-CD4CF50C13F6Q90854827-22902961-6FA1-4EF6-9F05-CA3A713F5779Q91599094-DEF6C26E-0AEE-4C21-A3A1-BC7CE39A8DACQ91776385-ECC94C84-651D-4271-81F8-EE3D3B2C080CQ92150024-0F2470D8-B970-463A-A0AA-EFECA7604F6CQ92291110-253661B3-B2AA-4791-840A-0F918C49BFD1Q92495783-BA2D3779-8606-45C4-861D-00F8571A3EFFQ92524119-36F2BBA2-C94E-468C-896F-D7D24C92AD4CQ92641345-741606D5-56CA-4922-AFB9-60B9F7F6426BQ93086041-811CE12C-D366-4B57-999A-6B2CD2A3BBF2
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Taku Nakashima
@ast
Taku Nakashima
@en
Taku Nakashima
@es
Taku Nakashima
@sl
type
label
Taku Nakashima
@ast
Taku Nakashima
@en
Taku Nakashima
@es
Taku Nakashima
@sl
prefLabel
Taku Nakashima
@ast
Taku Nakashima
@en
Taku Nakashima
@es
Taku Nakashima
@sl
P1053
D-1517-2011
P106
P31
P3829
P3835
taku-nakashima
P496
0000-0002-0035-674X
P569
2000-01-01T00:00:00Z